

TPW

Attorney Docket No. 60020200-0009

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)	Group Art Unit: 1645
)	
Anil K. CHAUHAN)	Examiner:
)	
Application No. 10/777,954)	
)	
Filed: February 12, 2004)	
)	
For: Immune Complexes)	
)	
)	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. § 1.97(b))**

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b).

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.


The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Respectfully submitted,

Dated: 8.10.04

By: 

Michael T. Marrah, Reg. No. 40,718
Customer No. 26263
314-259-5303




Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/777,954
				Filing Date	February 12, 2004
				First Named Inventor	Anil K. Chauhan
				Group Art Unit	1645
				Examiner Name	
Sheet 1 of 4				Attorney Docket Number 60020200-0009	
U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US 2002/0009771 A1	01-24-2002	Hinuma et al.	
	2	US 2001/0034028 A1	10-25-2001	Link et al.	
	3	US-6,519,611 B1	02-11-2003	Zong	
	4	US-6,264,623 B1	07-24-1001	Strahilevitz	
	5	US-6,251,394 B1	06-26-2001	Nilsson et al.	
	6	US-6,221,315 B1	04-24-2001	Giesler et al.	
	7	US-6,210,904 B1	04-03-2001	Bednar et al.	
	8	US-6,080,404	06-27-2000	Branham et al.	
	9	US-6,030,614	02-29-2000	Muller-Derlich et al.	
	10	US-5,869,047	02-09-1999	Blake	
	11	US-5,855,616	01-05-1999	Fournier et al.	
	12	US-5,853,722	12-29-1998	Rollins et al.	
	13	US-5,783,087	07-21-1998	Vlock, et al.	
	14	US-5,782,792	07-21-1998	Jones et al.	
	15	US-5,710,009	01-20-1998	Fitzpatrick et al.	
	16	US-5,593,897	01-14-1997	Potempa et al.	
	17	US-5,484,396	01-16-1996	Naficy	
	18	US-5,356,374	10-18-1994	Hogan et al.	
	19	US-5,314,624	05-24-1994	Kawakura et al.	
	20	US-5,277,701	01-11-1994	Christie et al.	
	21	US-5,245,038	09-14-1993	Hale et al.	
	22	US-5,221,628	06-22-1993	Anderson, et al.	
	23	US-5,223,441	06-29-1993	Ullman, et al.	
	24	US-5,211,850	05-18-1993	Shettigar et al.	
	25	US-5,122,112	06-16-1992	Jones	
	26	US-5,037,649	08-06-1991	Balint, Jr. et al.	
	27	US-4,945,039	07-31-1990	Suzuki, et al.	
	28	US-4,925,920	05-15-1900	Mannick et al.	
	29	US-4,925,788	05-15-1990	Liberti	
	30	US-4,783,525	11-08-1988	McDonald	
	31	US-4,708,713	11-24-1987	Lentz	
	32	US-4,685,900	08-11-1987	Honard et al.	
	33	US-4,664,913	05-12-1987	Mielke et al.	
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/777,954
				Filing Date	February 12, 2004
				First Named Inventor	Anil K. Chauhan
				Group Art Unit	1645
Examiner Name					
Sheet	2	of	4	Attorney Docket Number	60020200-0009
U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	34	US-4,627,915	12-9-1986	Kuroda et al.	
	35	US-4,551,435	11-05-1985	Liberti et al.	
	36	US-4,512,763	04-23-1985	Schneider	
	37	US-4,464,165	08-07-1984	Pollard, Jr.	
Examiner Signature					Date Considered



Please type a plus sign (+) inside this box ☒

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info unless it contains a valid OMB control no.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/777,954
				Filing Date	February 12, 2004
				First Named Inventor	Anil K. Chauhan
				Group Art Unit	1645
Examiner Name					
Attorney Docket No.	60020200-0009				
OTHER ITEMS – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T²
	38	AMIGORENA et al., "FcγRII Expression in Resting and Activated B Lymphocytes," European J. Immunology, 1989, pp. 1379-1385, Vol. 19.			
	39	ANDERSON et al., "Phagocytosis Mediated by Three Distinct Fcγ Receptor Classes on Human Leukocytes," J. Experimental Med., 1990, pp. 1333-1345, Vol. 171.			
	40	ASANUMA et al., "Clinical Hepatic Support By On-Line Plasma Treatment with Multiple Sorbents - Evaluation of System Performance," Trans. Am. Soc. Artif. Intern. Organs, 1980, pp. 400-405, Vol. XXVI.			
	41	BARTOK et al., "Comparison of the Binding of C3S and C3F to Complement Receptors Types 1, 2, and 3," J. of Immunology, 1995, pp. 5367-5375, Vol. 154.			
	42	CAUDWELL et al., "Complement Alternative Pathway Activation and Control on Membranes of Human Lymphoid B Cell Lines," European J. Immunology, 1990, pp. 2643-2650, Vol. 20.			
	43	ESPOSITO-FARESE et al., "Membrane and Soluble FcγRII/III Modulate the Antigen-Presenting Capacity of Murine Dendritic Epidermal Langerhans Cells for IgG-Complexed Antigens," J. Immunology, 1995, pp. 1725-1736, Vol. 154.			
	44	FRADE et al., "Analysis of gp140, a C3B-Binding Membrane Component Present on Raji Cells: A Comparison with Factor H," European J. Immunology, 1984, pp. 542-548, Vol. 14.			
	45	GRIFFIN et al., "Chapter 44 - Plasmapheresis and Immunoabsorption," Maneuvers/Additional Interventions, pp. 597-611.			
	46	KUNKEL et al., "Selective Removal of Circulating Immune Complexes from Patient Plasma," Artificial Organs, 2002, pp. 124-132, Vol. 26.			
	47	MUTA et al., "A 13-Amino-Acid Motif in the Cytoplasmic Domain of FcγRIIB Modulates B-Cell Receptor Signalling," Nature, 1994, pp. 70-73, Vol. 368.			
	48	PELTZ et al., "Cloned and Expressed Human Fc Receptor for IgG Mediates Anti-CD3-Dependent Lymphoproliferation," J. Immunology, 1988, pp. 1891-1896, Vol. 141.			
	49	PFUELLER et al., "Successful Treatment of Patients with Systemic Lupus Erythematosus by Immunoabsorption with a C1q Column: A Pilot Study," Arthritis & Rheumatism, 2001, pp. 1962-1963, Vol. 44.			
	50	PHILLIPS et al., "Cross-Linking of B Lymphocyte Fcγ Receptors and Membrane Immunoglobulin Inhibits Anti-Immunoglobulin-Induced Blastogenesis," J. Immunology, 1984, pp. 627-632, Vol. 132.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/777,954
				Filing Date	February 12, 2004
				First Named Inventor	Anil K. Chauhan
				Group Art Unit	1645
Examiner Name					
Attorney Docket No.	60020200-0009				
OTHER ITEMS – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T²
	51	RAMOS et al., "Complement-Dependent Cellular Cytotoxicity: Lymphoblastoid Lines That Activate Complement Component 3 (C3) and Express C3 Receptors Have Increased Sensitivity to Lymphocyte-Mediated Lysis in the Presence of Fresh Human Serum," Proceedings of the National Academy of Sciences of USA, 1985, pp. 5470-5474, Vol. 82.			
	52	SAMUELSSON, "Extracorporeal Immunoabsorption with Protein A: Technical Aspects and Clinical Results," J. Clinical Apheresis, 2001, pp. 49-52, Vol. 16.			
	53	SANDOR et al., "Lymphocyte Fc Receptors: The Special Case of T Cells," Immunology Today, 1992, p. 227-231, Vol. 14.			
	54	WIESENHUTTER et al., "Treatment of Patients with Refractory Rheumatoid Arthritis with Extracorporeal Protein A Immunoabsorption Columns: A Pilot Trial," J. Rheumatol., 1994, pp. 804-812, Vol. 21.			
	55	WERNERSSON et al., "IgG-Mediated Enhancement of Antibody Responses is Low in Fc Receptor γ Chain-Deficient Mice and Increased in Fc γ RII-Deficient Mice," J. Immunology, 1999, pp. 618-622, Vol. 163.			
	56	SUZUKI, KIMIHIRO, et al., "Adsorption of Anti-Annexin V Using Dextran Sulfate Bound Cellulose Beads," Journal of Clinical Apheresis 15:262-265 (2000).			
	57	McLEOD, BRUCE C., "Introduction to the Third Special Issue: Clinical Applications of Therapeutic Apheresis," Journal of Clinical Apheresis 15:1-5 (2000).			
Examiner Signature				Date Considered	